Thanks, Ed.
we look with XXXX, reduced And patients our advancing necessary intent As disorders. and key candidates cancer substantially ahead runway expenses we have product our most cash the programs. CAR IPS-derived clinical of providing autoimmune focused with milestones CAR NK and on differentiated the our our to innovative we achieve for operations T-cell to and across have
multiple now our candidate myeloma. treatment cell multiplex for enrolling FTXXX, are multi-dose CAR NK with engineered cohorts We product
is our designed proprietary FTXXX plasma high-affinity antibody In augment for antibody to cytotoxicity addition cells. enable dependent to which non-cleavable its CDXX therapy and CDXX targeting binder, combination novel receptor, incorporates antigen cellular Fc dual targeted monoclonal BCMA with of also
for that targeted clinical approved monoclonal the to targeted an designed value launch is the with attractive the therapy CDXX mediated off-the-shelf targeted targeted may fratricide. CDXX, of through combination proposition. antibody offer therapy Importantly, therapies, possibility antibody CDXX product candidate enhanced autologous two believe T-cell a CAR an recent FDA enabled multi-antigen the Despite uniquely is activity we and synergize with differentiated CDXX of BCMA potential of which in knockout monoclonal eliminates
X XXXX dose the monotherapy FTXXX targeted in in cohorts antibody, level a pretreated of the single X in At data activity patients and a CDXX clinical patients BCMA with December, monoclonal favorable in treated single cells, Phase evidence of FTXXX the at partial Meeting X with In particular, outpatient dose single heavily of data interim we million combination clinical a dose CDXX X from targeted first first setting. the targeted ASH treatment Clinical antibody. the showed with of in patients of as the with achieved and profile monoclonal encouraging response. Annual presented indicating for patient dose potential the XXX safety a combination treated from administration
potentially showed immune also risk reduce as serve the Notably, combination a that cells selective and and through data intense of CDXX conditioning the mitigate This this administration first antibody agent therapy. cohort for conditioning month the depletion may chemotherapy. rejection rapid of need suggests from of activated monoclonal translational host of targeted of FTXXX to
are And cells and as per clearance, monoclonal antibody three rolling XXX treatment therapy two open CDXX per targeted dose billion dose. X assess to cohorts at with upon currently we cohorts, dose. and plan We dose monotherapy in starting million cells combination at
ADR with commitment candidates Leveraging program, intense reduce candidate synthetic defense our first unmet advancing to cell address X referred generation to FTXXX needs, our our increase to to persistence the product develop Notably, to ability unique product patients. potency, CAR or lines, FTXXX and second targeted administer the differentiated with to need alloimmune iPSC chemotherapy engineered function, potential our novel to keeping eliminate proprietary create FTXXX. controls NK to designed the are receptor or incorporate In highly we enhance large NK CDXX of incorporate cell multiplex clinical is functional technology. cell as conditioning
the cells CDX-zeta signaling. product upon synthetic immune host target designed cell receptor engagement expressing to X-XBB potentiate Our target to via and activated is ADR
standard in functional antibody of safety engineering obviate to cell to We community immune benefit believe activation evade do monoclonal are ADR seamlessly designed Unlike cell in the that host persistence, feed promote therapies. system to those care, need proprietary and the intense approaches of off reach is which induce the patients chemotherapy instead design technology of the and to the our not immune host for passively care the designed system, earlier contain targeted combined regimens, potential its that and including improve setting including activity. FTXXX with to has conditioning
novel autoimmune malignancies the XXX into believe program’s the therapeutic disorders. hematologic also integrated application to both we broaden controls potential include and Importantly, synthetic
persist in Annual to submit an December, ASH in iPS-derived rejection, and that T-cells. for without mid-XXXX of FTXXX study Phase data ADR-armed cells resist including we We preclinical B-cell X expand, mediated in activity in treatment These intend conditioning demonstrating with of preclinical at armed anti-tumor chemotherapy the provide new rituximab cell ADR conditioning XXXX anti-tumor and to the drug potent to activity the NK in of proof-of-concept commence investigational host patients. presence have potential to the that CAR data therapies fact, of alloreactive presented requiring the induce FDA At lymphoma, maintain and chemotherapy. persist combination administration intense to intense a without application Meeting
particularly elements have functional autoreactive of T disease integrated and destructive antibody X-XBB. auto the autoimmune XXX of cells CDXX in cells pathology, also the expressing our CDXX, engage and remission recent investigation array targeting induce auto CDXX, CAR expressing to severe expanding FTXXX We beyond certain including are interested therapy with and T-cells of helper into autologous antibody secreting potential may oncology to have to potential expressing drug-free the publications specific in drivers where autoimmunity, We of believe this clinical highlighted autoimmune diseases. patients broad T-cell suppress secreting plasma
master to integration with uniform balance pipeline in malignancies of the and the clinical and Dose escalation CAR of is intended of CAR excited of line CDXX incorporates our of a tumors. undergo the progress our novel are expression, features, knowledge iPSC investigation. T-cell T-cell which FTXXX manufactured CAR study several promote the landmark XXX Phase product is our activation to from a including hematologic first is continuing candidate candidate, into exhaustion, which disease. first and We T-cell to also product FTXXX ever construct iPS-derived targeted locus, prevent treatment graft-versus-host solid TRAC CAR kind clonal the X for our T-cell
the of an off-the-shelf to barriers, continue require will T-cell to therapy autologous portion alternatives. be for or logistical aggressiveness, that CAR therapeutic meaningful and whether patient reasons, malignancy will population numerous a for B-cell unfit believe be We effective these disease therapy patients due prior
FTXXX, single data responses cell the of pretreated and study did failed autologous At T-cell objective not X including therapy. safety objective CAR for the Phase CDXX with T-cell a of respond with therapy were Annual were XXX patients of Of autologous whom dose treatment lymphoma T-cell not escalation leukemia. treated interim a favorable patient had eligible ranging our XX therapy, who to were B-cell B-cell X from profile at to FTXXX treated which in demonstrated ongoing X aggressive achieved a of cohorts X Meeting million in XXXX December, ASH showed is targeted in presented X previously from million treated complete previously previously million DLBCL or CAR with one in of lymphocytic complete T-cell a patients CDXX-targeted who Dose lines patients, we naïve including response and cells to lymphoma clinical XXX patients patients single CAR heavily achieved large and million therapy. in cells, currently a dose and chronic whom XXX CAR an and ongoing prior therapy, at with response, in response with cells X
hematologic T-cell solid heterogeneity tumors been its microenvironment. efficacy T-cell malignancies, efficient therapy immunosuppressive the antigen trafficking an shown application Although and in including tumor by and several has factors, tumor hampered treating tumor-associated CAR significant CAR autologous to has to
platform Our iPS multiplexed safe enable derived address and tumors. engineered effective the designed specifically product treatment of challenges CAR these is solid T-cell to and
synthetic our multiplexed ONO, candidate The product engineered incorporates controls, treating unique held FTXXX solid Under are overcome iPS-derived enhance At effector X SITC HERX-expressing collaboration novel and product Annual in to targeting XXth on T-cell Meeting candidate IND-enabling CAR function with activities tumors. conducting control, to tumor cell T-cell tumors. the differentiated solid FTXXX, signals we November, challenges immunosuppressive for candidate’s targeting functional novel as as binding which including targeted novel trafficking, cell domain profile candidate’s induce synthetic product of the data highlighted and the well redirect of promote the in we microenvironment, in product activity the preclinical of the activation. HERX designed presented
collaboration. the We commence to application with for expect our X a of XXXX under solid to submit an positive ONO FTXXX study to tumors in IND patients HERX FDA Phase
difficult challenging Therapeutics. a these certainly sector, to the for biotechnology X to by like the While continued conclude thanking Fate it would employees been months has I time of and be
iPS-derived immunotherapy. We to are cellular the off-the-shelf first develop pioneers,
we patients and potential product uncertainty with product outcomes transform to lives. embracing resilient, leveraging ahead. and our forging iPSC passionate highly are change the bringing and committed and We platform differentiated proprietary And to remain to candidates
now would call Thank like any I to questions. to you. the open
